We are a development stage biopharmaceutical company focused primarily on the development of pharmaceuticals to safely address one of the major underlying causes of many chronic diseases – inflammation – including cardiovascular disease, metabolic disease, liver disease, arthritis, and aging. We also have a commercial business unit that markets dietary supplements for inflammatory health. We believe we are well positioned for growth through the utilization of astaxanthin and zeaxanthin for chronic pharmaceutical applications by safely reducing chronic inflammation at the cellular and mitochondrial level – without inhibiting normal function. Similar mechanisms also support the use of our dietary supplement for inflammatory health.
Company profile
Ticker
CDXI
Exchange
Website
CEO
David G. Watumull
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Koffee Korner Inc.
SEC CIK
CDXI stock data
Latest filings (excl ownership)
D
$500K in debt / options / securities to be acquired / Convertible debt, sold $200K, 5 investors
30 Sep 21
8-K
Cardax Voluntarily Suspends SEC Reporting Obligations
11 Aug 21
15-15D
Suspension of duty to report
11 Aug 21
EFFECT
Notice of effectiveness
10 Aug 21
POS AM
Prospectus update (post-effective amendment)
5 Aug 21
8-K
Changes in Registrant's Certifying Accountant
1 Jul 21
10-Q
2021 Q1
Quarterly report
14 May 21
10-K
2020 FY
Annual report
15 Apr 21
NT 10-K
Notice of late annual filing
31 Mar 21
RW
Registration withdrawal request
10 Mar 21
Latest ownership filings
Financial summary
Quarter (USD) | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 58.65 k | 58.65 k | 58.65 k | 58.65 k | 58.65 k | 58.65 k |
Cash burn (monthly) | (no burn) | (no burn) | 460.71 k | 452.90 k | 112.37 k | 129.99 k |
Cash used (since last report) | n/a | n/a | 16.96 mm | 16.68 mm | 4.14 mm | 4.79 mm |
Cash remaining | n/a | n/a | -16.91 mm | -16.62 mm | -4.08 mm | -4.73 mm |
Runway (months of cash) | n/a | n/a | -36.7 | -36.7 | -36.3 | -36.4 |
Institutional ownership, Q4 2020
8.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 67.84 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sonora Investment Management | 67.84 k | $0.00 |